Wong-Beringer A - Search Results

1

Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.

Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Humphries RM, et al. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01858-17. doi: 10.1128/AAC.01858-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 28993338 Free PMC article.

2

Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.

Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, Quinn JP, Bush K. Wong-Beringer A, et al. Clin Infect Dis. 2002 Jan 15;34(2):135-46. doi: 10.1086/324742. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740699

3

Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.

Kriengkauykiat J, Porter E, Lomovskaya O, Wong-Beringer A. Kriengkauykiat J, et al. Antimicrob Agents Chemother. 2005 Feb;49(2):565-70. doi: 10.1128/AAC.49.2.565-570.2005. Antimicrob Agents Chemother. 2005. PMID: 15673734 Free PMC article.

4

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.

Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Hsu DI, et al. J Antimicrob Chemother. 2005 Apr;55(4):535-41. doi: 10.1093/jac/dki026. Epub 2005 Feb 22. J Antimicrob Chemother. 2005. PMID: 15728150

5

Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.

Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J. Wong-Beringer A, et al. Clin Microbiol Infect. 2008 Apr;14(4):330-6. doi: 10.1111/j.1469-0691.2007.01939.x. Epub 2008 Jan 11. Clin Microbiol Infect. 2008. PMID: 18190571 Free article.

6

Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.

Nguyen LH, Hsu DI, Ganapathy V, Shriner K, Wong-Beringer A. Nguyen LH, et al. J Antimicrob Chemother. 2008 Mar;61(3):714-20. doi: 10.1093/jac/dkm510. Epub 2008 Jan 25. J Antimicrob Chemother. 2008. PMID: 18222951

7

Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.

Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A. Hsu DI, et al. Int J Antimicrob Agents. 2008 Nov;32(5):378-85. doi: 10.1016/j.ijantimicag.2008.05.007. Epub 2008 Aug 12. Int J Antimicrob Agents. 2008. PMID: 18701261

8

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.

Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Minejima E, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83. doi: 10.1128/AAC.00173-11. Epub 2011 May 16. Antimicrob Agents Chemother. 2011. PMID: 21576448 Free PMC article.

9

Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins.

Yamaki J, Synold T, Wong-Beringer A. Yamaki J, et al. Antimicrob Agents Chemother. 2011 Sep;55(9):4432-5. doi: 10.1128/AAC.00122-11. Epub 2011 Jun 13. Antimicrob Agents Chemother. 2011. PMID: 21670179 Free PMC article.

10

Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa.

Agnello M, Wong-Beringer A. Agnello M, et al. PLoS One. 2012;7(8):e42973. doi: 10.1371/journal.pone.0042973. Epub 2012 Aug 8. PLoS One. 2012. PMID: 22905192 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters